Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Precipio reports preliminary Q2 revenue $2.3M, one est. $3.25M » 10:07
07/28/21
07/28
10:07
07/28/21
10:07
PRPO

Precipio

$3.20 /

+0.27 (+9.22%)

"I'm proud of…

"I'm proud of our team that has continued to work diligently to grow the Pathology business. Furthermore, Taking a technology developed at Precipio and creating a proprietary and protected product with meaningful clinical and economic benefit to our customers, is an example of our development capabilities," said Ilan Danieli, Precipio's CEO. "HemeScreen has an opportunity to be a world-wide technology as it continues to prove itself as a game-changing technology."

ShowHide Related Items >><<
PRPO Precipio
$3.20 /

+0.27 (+9.22%)

PRPO Precipio
$3.20 /

+0.27 (+9.22%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
PRPO Precipio
$3.20 /

+0.27 (+9.22%)

PRPO Precipio
$3.20 /

+0.27 (+9.22%)

Over a month ago
Hot Stocks
Precipio terminates equity line financing structure with Lincoln Park Capital » 11:01
06/15/21
06/15
11:01
06/15/21
11:01
PRPO

Precipio

$4.28 /

+0.3 (+7.54%)

Precipio announces that…

Precipio announces that as part of management's review of its current financing arrangements, it has terminated the equity line financing structure it had in place with Lincoln Park Capital. The equity line was used by Precipio to fund day-to-day operations and cover its operational cash burn that was required for the company's continued growth. With the company's current situation - growing revenues, improved gross margins, improving cash from gross profits - combined with our current cash position, management currently does not anticipate the need for additional capital raises of the type that Lincoln Park has provided us. "I'd like to thank our friends at Lincoln Park Capital for their help and support of the Company, particularly during the periods where this arrangement was critical to the Company's cash needs," said Ilan Danieli, Precipio's CEO. "We are now in a position where we have significantly extended our runway, and we anticipate that we will have the ability and the resources to rapidly grow the Company without further capital raises to fund ongoing operations in the next 24 months."

ShowHide Related Items >><<
PRPO Precipio
$4.28 /

+0.3 (+7.54%)

PRPO Precipio
$4.28 /

+0.3 (+7.54%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
PRPO Precipio
$4.28 /

+0.3 (+7.54%)

PRPO Precipio
$4.28 /

+0.3 (+7.54%)

Options
Largest borrow rate increases among liquid names » 08:45
06/14/21
06/14
08:45
06/14/21
08:45
ARVL

Arrival

$19.20 /

-0.555 (-2.81%)

, UPST

Upstart

$125.55 /

-20.89 (-14.27%)

, HTZGQ

Hertz

$1.79 /

+ (+0.00%)

, IPOF

Social Capital Hedosophia Holdings Corp. VI

$10.33 /

+0.045 (+0.44%)

, ATER

Aterian

$15.81 /

+0.14 (+0.89%)

, PRPO

Precipio

$3.84 /

+0.04 (+1.05%)

, CLII

Climate Change Crisis Real Impact I

$13.70 /

-0.05 (-0.36%)

, SPI

SPI Energy

$6.95 /

-0.32 (-4.40%)

, LHDX

Lucira Health

$5.59 /

+0.29 (+5.47%)

, BNGO

Bionano Genomics

$7.57 /

-0.075 (-0.98%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Arrival (ARVL) 270.81% +107.38, Upstart Holdings (UPST) 83.44% +6.61, Hertz Global Holdings (HTZGQ) 20.53% +4.64, Social Capital Hedosophia VI (IPOF) 5.59% +3.93, Aterian (ATER) 14.66% +2.58, Precipio (PRPO) 37.93% +1.72, Climate Change Crisis Real Impact I Acquisition Corp (CLII) 16.84% +1.05, SPI Energy (SPI) 27.28% +0.41, Lucira Health (LHDX) 49.49% +0.39, and Bionano Genomics (BNGO) 1.96% +0.31.

ShowHide Related Items >><<
UPST Upstart
$125.55 /

-20.89 (-14.27%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

PRPO Precipio
$3.84 /

+0.04 (+1.05%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

ATER Aterian
$15.81 /

+0.14 (+0.89%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

06/03/21 Barclays
Arrival initiated with an Overweight at Barclays
04/05/21 Cowen
Cowen starts Arrival at Outperform on 'unique microfactory approach'
04/05/21 Cowen
Arrival initiated with an Outperform at Cowen
UPST Upstart
$125.55 /

-20.89 (-14.27%)

05/12/21 JMP Securities
Upstart price target raised to $149 from $111 at JMP Securities
05/12/21 Piper Sandler
Upstart price target raised to $152 from $143 at Piper Sandler
04/27/21
Fly Intel: Top five analyst initiations
04/27/21 Piper Sandler
Upstart initiated with an Overweight at Piper Sandler
HTZGQ Hertz
$1.79 /

+ (+0.00%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

ATER Aterian
$15.81 /

+0.14 (+0.89%)

05/07/21 Alliance Global Partners
Alliance Global says Aterian stock oversold, calls a top pick after recent drop
05/05/21 Roth Capital
Aterian price target lowered to $30 from $40 at Roth Capital
PRPO Precipio
$3.84 /

+0.04 (+1.05%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

05/04/21 William Blair
William Blair downgrades Lucira Health on slowing Covid testing volumes
05/04/21 William Blair
Lucira Health downgraded to Market Perform from Outperform at William Blair
04/13/21
Fly Intel: Top five analyst downgrades
04/13/21 BofA
Lucira Health downgraded to Underperform from Buy at BofA
BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
UPST Upstart
$125.55 /

-20.89 (-14.27%)

PRPO Precipio
$3.84 /

+0.04 (+1.05%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

  • 09
    Apr
  • 05
    Feb
  • 20
    Jan
  • 08
    Jan
  • 16
    Dec
  • 01
    Oct
IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

UPST Upstart
$125.55 /

-20.89 (-14.27%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

UPST Upstart
$125.55 /

-20.89 (-14.27%)

SPI SPI Energy
$6.95 /

-0.32 (-4.40%)

PRPO Precipio
$3.84 /

+0.04 (+1.05%)

LHDX Lucira Health
$5.59 /

+0.29 (+5.47%)

IPOF Social Capital Hedosophia Holdings Corp. VI
$10.33 /

+0.045 (+0.44%)

HTZGQ Hertz
$1.79 /

+ (+0.00%)

CLII Climate Change Crisis Real Impact I
$13.70 /

-0.05 (-0.36%)

BNGO Bionano Genomics
$7.57 /

-0.075 (-0.98%)

ATER Aterian
$15.81 /

+0.14 (+0.89%)

ARVL Arrival
$19.20 /

-0.555 (-2.81%)

Hot Stocks
Precipio launches HemeScreen Anemia Panel » 10:31
06/08/21
06/08
10:31
06/08/21
10:31
PRPO

Precipio

$3.58 /

+0.04 (+1.13%)

Precipio announced that…

Precipio announced that it has launched the HemeScreen Anemia Panel as part of its suite of diagnostic tests. The purpose of this panel is to help physicians address one of the more significant clinical challenges they face: anemia of unknown cause. Precipio's HemeScreen Anemia Panel is a simple blood test that identifies molecular genetic errors which point to potentially fatal acute leukemia. Precipio's rapid, simple test, performed in the doctor's office, directs the physician to perform further appropriate hematology testing and treatment.

ShowHide Related Items >><<
PRPO Precipio
$3.58 /

+0.04 (+1.13%)

PRPO Precipio
$3.58 /

+0.04 (+1.13%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
PRPO Precipio
$3.58 /

+0.04 (+1.13%)

PRPO Precipio
$3.58 /

+0.04 (+1.13%)

Options
new option listings and three option delistings on May 26th » 08:30
05/26/21
05/26
08:30
05/26/21
08:30
AVAH

Aveanna

$11.26 /

-0.26 (-2.26%)

, BCM

Canadian Imperial Bank of Commerce (CIBC)

$35.58 /

+0.43 (+1.22%)

, BDSX

Biodesix

$14.87 /

+0.71 (+5.01%)

, BIPC

Brookfield Infrastructure

$70.01 /

+0.6 (+0.86%)

, CAPE

Cape Fear Bank

$205.10 /

-0.38 (-0.18%)

, CGAU

Centerra Gold

$7.78 /

-0.3047 (-3.77%)

, DSPC

DSP Communications

$25.31 /

-0.14 (-0.55%)

, GRN

General Re Corporation

$104.22 /

+0.07 (+0.07%)

, GSP

Growth Fund of Spain

$14.53 /

+0.08 (+0.55%)

, LD

Louis Dreyfus Natural Gas

$44.95 /

+ (+0.00%)

, MMX

Maverix Metals

$5.92 /

-0.26 (-4.21%)

, OIL

Triton Energy

$19.50 /

+0.14 (+0.72%)

, OTLY

Oatly Group

$21.17 /

+0.47 (+2.27%)

, PRPO

Precipio

$3.73 /

-0.11 (-2.86%)

, SWIM

Latham Group

$29.96 /

+0.36 (+1.22%)

, CUB

Cubic

$75.01 /

+ (+0.00%)

, FFG

FBL Financial

$60.99 /

+0.035 (+0.06%)

, GFN

General Finance Corp

$19.01 /

+0.005 (+0.03%)

New option listings for…

New option listings for May 26th include Barclays ETN Plus Select MLP (ATMP), Aveanna Healthcare Holdings Inc (AVAH), iPath Pure Beta Broad Commodity (BCM), Biodesix Inc (BDSX), Brookfield Infrastructure Corporation (Class A Stock) (BIPC), Barclays ETN plus Shiller CAPE (CAPE), Centerra Gold Inc (CGAU), iPath US Treasury 5-year Bull (DFVL), iPath US Treasury 5-year Bear (DFVS), De spac ETF (DSPC), iPath Series B Bloomberg Natural Gas Subindex TR ETN (GAZ), Pacer iPath Gold ETN (GBUG), iPath Series B Carbon ETN (GRN), Barclays Bank Plc (GSP), iPath S&P (IMLP), iPath Series B Bloomberg Energy Subindex TR ETN (JJE), iPath Series B Bloomberg Softs Subindex TR ETN (JJS), iPath Bloomberg Lead Subindex Total Return ETN (LD), Maverix Metals Inc (MMX), iPath Pure Beta Crude Oil (OIL), Oatly Group AB (ADS) (OTLY), iPath Series B Bloomberg Platinum Subindex TR ETN (PGM), Precipio Inc (PRPO), AB Svensk Ekportkredit (RJZ), and Latham Group Inc (SWIM). Option delistings effective May 26th include Cubic Corp (CUB), FBL Financial Group Inc (Class A Stock) (FFG), and General Finance Corp (GFN).

ShowHide Related Items >><<
PRPO Precipio
$3.73 /

-0.11 (-2.86%)

MMX Maverix Metals
$5.92 /

-0.26 (-4.21%)

GFN General Finance Corp
$19.01 /

+0.005 (+0.03%)

FFG FBL Financial
$60.99 /

+0.035 (+0.06%)

CUB Cubic
$75.01 /

+ (+0.00%)

CGAU Centerra Gold
$7.78 /

-0.3047 (-3.77%)

BDSX Biodesix
$14.87 /

+0.71 (+5.01%)

AVAH Aveanna
$11.26 /

-0.26 (-2.26%)

05/24/21 RBC Capital
Aveanna initiated with an Outperform at RBC Capital
05/24/21 Jefferies
Aveanna initiated with a Buy at Jefferies
05/24/21 Raymond James
Aveanna initiated with a Strong Buy at Raymond James
05/24/21 JPMorgan
Aveanna initiated with a Neutral at JPMorgan
BCM Canadian Imperial Bank of Commerce (CIBC)
$35.58 /

+0.43 (+1.22%)

BDSX Biodesix
$14.87 /

+0.71 (+5.01%)

03/18/21 Morgan Stanley
Biodesix price target raised to $25 from $20 at Morgan Stanley
03/17/21 Canaccord
Biodesix a rare opportunity in precision oncology, says Canaccord
02/02/21 Canaccord
Biodesix price target raised to $31 from $27 at Canaccord
01/11/21 Canaccord
Biodesix price target raised to $27 from $26 at Canaccord
BIPC Brookfield Infrastructure
$70.01 /

+0.6 (+0.86%)

01/06/21 Wells Fargo
Wells Fargo says buy CenterPoint Energy, sell FirstEnergy
01/06/21 Wells Fargo
Brookfield Infrastructure downgraded to Equal Weight from Overweight at Wells Fargo
11/23/20 Credit Suisse
Brookfield Infrastructure Partners upgraded to Neutral at Credit Suisse
05/27/20 BofA
Brookfield Infrastructure initiated with a Buy at BofA
CAPE Cape Fear Bank
$205.10 /

-0.38 (-0.18%)

CGAU Centerra Gold
$7.78 /

-0.3047 (-3.77%)

05/20/21 National Bank
Centerra Gold price target raised to C$11.25 from C$10.25 at National Bank
05/19/21 CIBC
Centerra Gold price target lowered to C$9 from C$10 at CIBC
05/19/21 Raymond James
Centerra Gold price target raised to C$10.50 from C$10.25 at Raymond James
05/19/21 Scotiabank
Centerra Gold price target raised to C$10.50 from C$8 at Scotiabank
DSPC DSP Communications
$25.31 /

-0.14 (-0.55%)

GRN General Re Corporation
$104.22 /

+0.07 (+0.07%)

GSP Growth Fund of Spain
$14.53 /

+0.08 (+0.55%)

LD Louis Dreyfus Natural Gas
$44.95 /

+ (+0.00%)

MMX Maverix Metals
$5.92 /

-0.26 (-4.21%)

05/20/21 National Bank
Maverix Metals price target raised to C$8 from C$7.75 at National Bank
05/20/21 Canaccord
Maverix Metals upgraded to Buy from Hold at Canaccord
04/23/21 National Bank
Maverix Metals price target raised to C$7.75 from C$7.50 at National Bank
04/21/21 Canaccord
Maverix Metals downgraded to Hold from Buy at Canaccord
OIL Triton Energy
$19.50 /

+0.14 (+0.72%)

OTLY Oatly Group
$21.17 /

+0.47 (+2.27%)

PRPO Precipio
$3.73 /

-0.11 (-2.86%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
SWIM Latham Group
$29.96 /

+0.36 (+1.22%)

05/18/21
Fly Intel: Top five analyst initiations
05/18/21 KeyBanc
KeyBanc bullish on Latham Group, initiates with an Overweight
05/18/21 Truist
Truist starts 'secular growth story' Latham Group at Buy
05/18/21 Baird
Latham Group to solidify fiberglass lead, Baird starts with Outperform
CUB Cubic
$75.01 /

+ (+0.00%)

02/09/21
Fly Intel: Top five analyst downgrades
02/09/21 Needham
Cubic downgraded to Hold from Buy at Needham
02/09/21 Truist
Cubic downgraded to Hold from Buy at Truist
02/09/21 Needham
Cubic downgraded to Hold from Buy at Needham
FFG FBL Financial
$60.99 /

+0.035 (+0.06%)

05/04/21 Raymond James
FBL Financial double downgraded to Underperform at Raymond James
05/04/21 Raymond James
FBL Financial downgraded to Underperform from Outperform at Raymond James
09/04/20 Sidoti
FBL Financial downgraded to Neutral from Buy at Sidoti
08/19/20
Fly Intel: Top five analyst upgrades
GFN General Finance Corp
$19.01 /

+0.005 (+0.03%)

05/06/21 DA Davidson
General Finance Corp downgraded to Neutral from Buy at DA Davidson
05/06/21 DA Davidson
General Finance Corp downgraded to Neutral from Buy at DA Davidson
PRPO Precipio
$3.73 /

-0.11 (-2.86%)

GFN General Finance Corp
$19.01 /

+0.005 (+0.03%)

FFG FBL Financial
$60.99 /

+0.035 (+0.06%)

CUB Cubic
$75.01 /

+ (+0.00%)

BDSX Biodesix
$14.87 /

+0.71 (+5.01%)

  • 20
    May
  • 29
    Apr
  • 23
    Apr
  • 28
    Oct
  • 29
    May
OTLY Oatly Group
$21.17 /

+0.47 (+2.27%)

CUB Cubic
$75.01 /

+ (+0.00%)

SWIM Latham Group
$29.96 /

+0.36 (+1.22%)

OTLY Oatly Group
$21.17 /

+0.47 (+2.27%)

CUB Cubic
$75.01 /

+ (+0.00%)

CGAU Centerra Gold
$7.78 /

-0.3047 (-3.77%)

AVAH Aveanna
$11.26 /

-0.26 (-2.26%)

Hot Stocks
Precipio launches COVID-19 rapid antibody test on Amazon's business platform » 09:32
05/03/21
05/03
09:32
05/03/21
09:32
PRPO

Precipio

$1.82 /

-0.04 (-2.15%)

, AMZN

Amazon.com

$3,465.83 /

-4.98 (-0.14%)

Precipio (PRPO) announced…

Precipio (PRPO) announced that it has successfully launched its COVID-19 rapid antibody test which tests for both IgG & IgM antibodies, on Amazon.com's (AMZN) business platform. Precipio holds the exclusive rights to distribute this product on Amazon's platform. The antibody test, which is manufactured in the USA by Nirmidas Biotech, of California, was the first US-based test to receive emergency use authorization by the FDA for point-of-care. The product is visible for sale on Amazon's website and app, per the EUA approval received for the test kit in December of 2020; however it may currently be purchased only by qualified medical point-of-care providers. Physicians and other medical facilities may now purchase these items directly from Amazon, and receive them within 2 business days.

ShowHide Related Items >><<
PRPO Precipio
$1.82 /

-0.04 (-2.15%)

AMZN Amazon.com
$3,465.83 /

-4.98 (-0.14%)

PRPO Precipio
$1.82 /

-0.04 (-2.15%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
AMZN Amazon.com
$3,465.83 /

-4.98 (-0.14%)

04/30/21 Evercore ISI
Amazon price target raised to $4,500 from $4,000 at Evercore ISI
04/30/21 MKM Partners
Amazon.com price target raised to $4,075 from $3,975 at MKM Partners
04/30/21 Raymond James
Amazon.com price target raised to $4,125 from $4,000 at Raymond James
04/30/21 Truist
Amazon.com price target raised to $4,000 from $3,750 at Truist
PRPO Precipio
$1.82 /

-0.04 (-2.15%)

AMZN Amazon.com
$3,465.83 /

-4.98 (-0.14%)

AMZN Amazon.com
$3,465.83 /

-4.98 (-0.14%)

AMZN Amazon.com
$3,465.83 /

-4.98 (-0.14%)

AMZN Amazon.com
$3,465.83 /

-4.98 (-0.14%)

Over a quarter ago
Hot Stocks
Precipio expects $1M annualized reported revenues from HemeScreen POL by Q4 » 11:02
04/26/21
04/26
11:02
04/26/21
11:02
PRPO

Precipio

$1.94 /

-0.005 (-0.26%)

Precipio announced that…

Precipio announced that currently, the contracted annualized revenues from signed customers for its HemeScreen POL testing system exceed $750,000 and for the reasons set forth below, by Q4-2021 this cohort is expected to result in reported quarterly revenues with an annualized run rate of $1,000,000. With an additional pipeline of over 30 prospective customers nationwide, Precipio currently reaffirms its forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021. The annualized reported revenues from the cohort of current signed customers are expected to increase to $1,000,000 by Q4-2021 because newly signed customers typically make smaller contractual commitments in order to evaluate their work flow and HemeScreen utility before committing to a larger number. In addition, during the coming months the HemeScreen offering is anticipated to broaden by the introduction of additional panels for other types of cancer. If successful, this expansion will improve patient care while providing meaningful financial benefits to customers' and to Precipio's bottom line. As Precipio continues to introduce additional assays to be utilized on the same platform, average revenue per customer will increase via incorporation and utilization of these assays within the POL's operations.

ShowHide Related Items >><<
PRPO Precipio
$1.94 /

-0.005 (-0.26%)

PRPO Precipio
$1.94 /

-0.005 (-0.26%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
PRPO Precipio
$1.94 /

-0.005 (-0.26%)

Hot Stocks
Precipio enters ATM financing arrangement » 09:10
04/05/21
04/05
09:10
04/05/21
09:10
PRPO

Precipio

$2.33 /

-0.035 (-1.48%)

Precipio announces a new…

Precipio announces a new "At-The-Market" financing arrangement that improves its financing flexibility. As provided in the Company's prospectus supplement filed on April 2, 2021, Precipio will be able to sell shares from time to time through the ATM offering, up to an aggregate of $20M. The Company anticipates that this will be its primary financing method going forward. The ATM will be managed by Alliance Global Partners, an investment bank with which Precipio has been working since 2017. This arrangement will be used in an ongoing manner to finance Precipio's operations and provide the resources the Company needs to fuel its growth, particularly for its new HemeScreen offering for physician offices. As the Company continues to grow, having the most cost-effective, flexible financial tools at its disposal is critical to financing in the least dilutive manner. The ATM structure provides Precipio's management with more control over the timing, pricing, and proceeds it receives from selling shares into the market.

ShowHide Related Items >><<
PRPO Precipio
$2.33 /

-0.035 (-1.48%)

PRPO Precipio
$2.33 /

-0.035 (-1.48%)

04/01/21 Maxim
Precipio price target raised to $7 from $2 at Maxim
PRPO Precipio
$2.33 /

-0.035 (-1.48%)

Recommendations
Precipio price target raised to $7 from $2 at Maxim » 08:07
04/01/21
04/01
08:07
04/01/21
08:07
PRPO

Precipio

$2.34 /

-0.055 (-2.30%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy raised the firm's price target on Precipio to $7 from $2 and keeps a Buy rating on the shares. The company's FY20 revenue grew in spite of the COVID headwinds, and while that growth was mainly attributed to the pathology services business, Precipio is shifting its core business toward the higher margin hematology diagnostic products and slowly away from sample selection and in-house testing, the analyst tells investors in a research note.

ShowHide Related Items >><<
PRPO Precipio
$2.34 /

-0.055 (-2.30%)

PRPO Precipio
$2.34 /

-0.055 (-2.30%)

Earnings
Precipio reports 2020 revenue $6.1M vs. $3.1M last year. » 09:16
03/30/21
03/30
09:16
03/30/21
09:16
PRPO

Precipio

$2.26 /

-0.01 (-0.44%)

"The efforts of our…

"The efforts of our team throughout the 2020 Covid shutdown were incredible, and the results speak for themselves", said Ilan Danieli, the Company's CEO. "We began to prepare in mid-March 2020 for the unknown; the individual efforts of our lab, R&D and sales personnel define the word "perseverance" and the phrase "commitment to excellence". We now have the opportunity to leverage a powerful growth engine which has been put through the challenges of 2020 and is ready for takeoff in 2021."

ShowHide Related Items >><<
PRPO Precipio
$2.26 /

-0.01 (-0.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.